Company intelligence / Profile preview

OptoCeutics

Ownership: Private
Development stage: Other

Overview

OptoCeutics' EVY LIGHT® device uses patented 40 Hz light-based gamma stimulation to target neural activity implicated in Alzheimer's and dementia. Early clinical studies indicate safety, feasibility, and potential positive effects on cognition. The technology is supported by collaborations with leading academic institutions and is currently being evaluated in further clinical research.

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapy (light-based neurostimulation)
Industry: Therapeutic Medical Devices

Partnerships

Danish Technical UniversityUniversity of California BerkeleyRoskilde University HospitalCopenhagen UniversityCITRIS Health at UC Berkeley

Beyond the preview

Go deeper on OptoCeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OptoCeutics.

Explore the full profile